{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["192(1)"],"submitter":["Kilmartin DJ"],"funding":["University College Dublin"],"pubmed_abstract":["Brolucizumab is a novel humanised, single-chain, variable fragment inhibitor of Vascular Endothelial Growth Factor-A for the treatment of neurovascular age-related macular degeneration. Brolucizumab gained US Food and Drug Administration and European Medicines Agency approval following the Phase III HAWK (NCT02307682) and HARRIER (NCT02434328) trials which compared brolucizumab with aflibercept, presenting a tolerable safety and favourable efficacy profile. The mean change (least squares [LS] mean ± standard error) in best-corrected visual acuity letters from baseline to week 96 in the HAWK trial was 5.9 ± 0.78 for brolucizumab (6 mg) versus 5.3 ± 0.78 for aflibercept, and in the HARRIER trial, 6.1 ± 0.73 (6 mg) for brolucizumab (6 mg) and 6.6 ± 0.73 for aflibercept. Within both trials, gr"],"journal":["Irish journal of medical science"],"pagination":["447-456"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9892069"],"repository":["biostudies-literature"],"pubmed_title":["Literature review and proposal of best practice for ophthalmologists: monitoring of patients following intravitreal brolucizumab therapy."],"pmcid":["PMC9892069"],"pubmed_authors":["Kilmartin DJ"],"additional_accession":[]},"is_claimable":false,"name":"Literature review and proposal of best practice for ophthalmologists: monitoring of patients following intravitreal brolucizumab therapy.","description":"Brolucizumab is a novel humanised, single-chain, variable fragment inhibitor of Vascular Endothelial Growth Factor-A for the treatment of neurovascular age-related macular degeneration. Brolucizumab gained US Food and Drug Administration and European Medicines Agency approval following the Phase III HAWK (NCT02307682) and HARRIER (NCT02434328) trials which compared brolucizumab with aflibercept, presenting a tolerable safety and favourable efficacy profile. The mean change (least squares [LS] mean ± standard error) in best-corrected visual acuity letters from baseline to week 96 in the HAWK trial was 5.9 ± 0.78 for brolucizumab (6 mg) versus 5.3 ± 0.78 for aflibercept, and in the HARRIER trial, 6.1 ± 0.73 (6 mg) for brolucizumab (6 mg) and 6.6 ± 0.73 for aflibercept. Within both trials, gr","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-05-29T19:43:55.914Z","creation":"2025-05-29T19:43:55.914Z"},"accession":"S-EPMC9892069","cross_references":{"pubmed":["35102497"],"doi":["10.1007/s11845-022-02929-8"]}}